A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Neal Rosen(Memorial Sloan Kettering Cancer Center), Allen Oliff(GlaxoSmithKline (United Kingdom)), Zhuang Ma, N. E. Kohl, W. Wayt Gibbs(United States Military Academy), Elaine Rands
PubMed
November 15, 1995
Cited by 385
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
|Nature|2011|1.4k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k